Peer-reviewed veterinary case report
COX-1 and COX-2 in dog rectal and bladder tumors study
By Knottenbelt, C et al.·Published in The Journal of small animal practice·2006·Department of Veterinary Clinical Studies, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
- Species:
- dog
Plain-English summary
A study looked at dogs with bladder tumors and rectal tumors to see how certain proteins (COX-1 and COX-2) might affect their cancer. In dogs with bladder cancer, all samples showed these proteins, while in rectal tumors, many samples were negative for one or both proteins. This difference could help explain why some dogs respond better to treatments like non-steroidal anti-inflammatory drugs than others. Understanding these variations may lead to more effective treatment options for dogs with these types of tumors.
People also search for: dog bladder cancer treatment · dog rectal tumor symptoms · COX-2 inhibitors for dogs
Abstract
OBJECTIVES: To determine the role that cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) play in malignant transformation in canine transitional cell carcinoma and rectal tumours. METHODS: Histological sections of 21 canine rectal adenocarcinomas and 18 canine transitional cell carcinomas were stained for COX-1 and COX-2. Mann-Whitney non-parametric tests were applied to determine if there was any relationship between the percentage of cells expressing COX-1 or COX-2, and between COX-1 and COX-2 staining intensity and age, breed or sex. RESULTS: For rectal adenocarcinomas, 19.0 per cent of the sections were negative for COX-1 and COX-2. A further 38.1 per cent of the sections were negative for COX-2 but positive for COX-1, and 38.1 per cent of the sections had rare or occasional single cells positive for COX-2. No significant differences were found in COX staining when compared with age, breed or sex. For transitional cell carcinomas, all of the sections were positive for COX-1 and COX-2. For COX-2 staining, 16.7 per cent had more than 30 per cent positive cells. For COX-1 staining, 38.9 per cent had more than 30 per cent positive cells. There was a significant increase in the percentage of COX-1 positive cells in small breed dogs (P = 0.0337). CLINICAL SIGNIFICANCE: The variations in COX expression reported in this study may explain the differences in the clinical response of transitional cell carcinomas and rectal adenocarcinomas following treatment with non-steroidal anti-inflammatory drugs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16573762/